Subject to the approval of listing of the GlucoTrack model DF-F device on the Australian Register of Therapeutic Goods register, Ultramedix Australasia’s appointment as distributor will take effect 14 days after the approval.

Ultramedix Australia, based on the minimum purchase requirements contained in the distribution agreement, is anticipated to purchase a minimum of $360,000 of GlucoTrack model DF-F devices from Integrity Applications in the first contract year.

Integrity Applications president and CEO Avner Gal noted this distribution agreement marks an important milestone for the company and it looks forward to providing patients with diabetes a new, non-invasive option for monitoring blood glucose.

"I am confident that the diabetes community in Australia and New Zealand, as well as other nations, will soon learn about the many benefits of GlucoTrack, and use this tool as a fresh alternative to existing blood glucose monitoring options," Gal added.

Integrity Applications has developed the GlucoTrack model DF-F device. The device features a small sensor which clips to the earlobe and measures the wearer’s blood glucose level by taking measurements using three technologies.

Using a proprietary algorithm, the device analyzes the measurements.

GlucoTrack received CE Mark approval in Europe. Integrity Applications is likely to seek the US Food and Drug Administration approval for the device in the US.